Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| DAVITA INC.DVA · Entity 3482 | Director | August 15, 2026 | August 18, 2026 |
| LABCORP HOLDINGS INC.LH · Entity 1277 | Director · President & CEO | August 11, 2026 | August 12, 2026 |
| Merck & Co., Inc.MRK · Entity 2807 | EVP & Pres-Global Human Health | November 01, 2018 | November 02, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
DAVITA INC.
Report date August 15, 2026 · Filed August 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 5,970 |
Reported balance
After 2026-08-15 transaction · row 1
1 source rowRow 1 · 2026-08-15 · Grant · Acquired 278 · Balance 5,970 |
LABCORP HOLDINGS INC.
Report date August 11, 2026 · Filed August 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 102,565 |
Reported balance
After 2026-08-11 transaction · row 1
1 source rowRow 1 · 2026-08-11 · Sale · Disposed 4,669 · Balance 102,565 F1: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
Merck & Co., Inc.
Report date November 01, 2018 · Filed November 02, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2018-11-01 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2018-11-01 · Exercise / conversion · Acquired 277,879 · Balance 277,879 Row 2 · 2018-11-01 · Sale · Disposed 132,744 · Balance 145,135 F1: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.6800 to $73.3900, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. Row 3 · 2018-11-01 · Sale · Disposed 145,135 · Balance 0 F1: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $73.4000 to $74.0200, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $39.29 · Expires 2022-05-01 | Direct | 0 |
Reported balance
After 2018-11-01 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2018-11-01 · Exercise / conversion · Disposed 277,879 · Balance 0 F5: The option became exercisable in equal installments on 5/2/2013, 5/2/2014 and 5/2/2015. |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 55,405.9747 |
Reported balance
Holding disclosure · report date 2018-11-01 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 55,405.9747 F4: Holdings include shares acquired in dividend reinvestment transactions. |
Filing footnotes · ownership attribution and instrument terms
F1: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.6800 to $73.3900, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $73.4000 to $74.0200, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
F4: Holdings include shares acquired in dividend reinvestment transactions.
F5: The option became exercisable in equal installments on 5/2/2013, 5/2/2014 and 5/2/2015.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 01, 2016 Filed Jul 1, 2016 17:13 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $44.30 | $0.00 |
DisclosureSEC source: 0001225208-16-035825 · doc4.xml · derivative · entry 4 Schechter Adam H · CIK 0001376841 · EVP & Pres-Global Human Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2018-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option became exercisable in equal installments on 2/28/2009, 2/28/2010 and 2/28/2011. Read SEC document |
| July 01, 2016 Filed Jul 1, 2016 17:13 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 50,000 | $57.69 | $2,884,415.00 |
DisclosureSEC source: 0001225208-16-035825 · doc4.xml · nonDerivative · entry 2 Schechter Adam H · CIK 0001376841 · EVP & Pres-Global Human Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.4300 to $57.9400, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. Read SEC document |
| July 01, 2016 Filed Jul 1, 2016 17:13 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 50,000 | $44.30 | $2,215,000.00 |
DisclosureSEC source: 0001225208-16-035825 · doc4.xml · nonDerivative · entry 1 Schechter Adam H · CIK 0001376841 · EVP & Pres-Global Human Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 10, 2016 Filed May 12, 2016 15:40 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 258,065 | $0.00 Strike: $54.68 | $0.00 |
DisclosureSEC source: 0001225208-16-033213 · doc4.xml · derivative · entry 2 Schechter Adam H · CIK 0001376841 · EVP & Pres-Global Human Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 258,065 Underlying: Common Stock · 258,065 shares Expires 2026-05-09 F2 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 5/10/2017, 5/10/2018 and 5/10/2019. Read SEC document |
| February 22, 2016 Filed Feb 24, 2016 17:38 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantCommon Stock | 37,223 | $50.77 | $1,889,811.71 |
DisclosureSEC source: 0001225208-16-027765 · doc4.xml · nonDerivative · entry 1 Schechter Adam H · CIK 0001376841 · EVP & Pres-Global Human Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,223 F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance share units granted on 03/29/2013. Performance shares were paid out at 105 percent of target awards. Read SEC document |
| May 11, 2015 Filed May 11, 2015 21:48 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 10,634 | $60.44 | $642,767.88 |
DisclosureSEC source: 0001225208-15-011867 · doc4.xml · nonDerivative · entry 1 Schechter Adam H · CIK 0001376841 · EVP & Pres-Global Human Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.3100 to $60.6400, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. Read SEC document |
| May 02, 2015 Filed May 5, 2015 20:46 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionRestricted Stock Unit · Derivative | 19,343 | $59.86 | $1,157,871.98 |
DisclosureSEC source: 0001225208-15-011279 · doc4.xml · derivative · entry 5 Schechter Adam H · CIK 0001376841 · EVP & Pres-Global Human Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 19,343 shares Expires 2015-05-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. Read SEC document |
| May 02, 2015 Filed May 5, 2015 20:46 UTC | Merck & Co., Inc. MRK · Entity 2807 | Tax withholdingCommon Stock | 8,709 | $59.86 | $521,320.74 |
DisclosureSEC source: 0001225208-15-011279 · doc4.xml · nonDerivative · entry 2 Schechter Adam H · CIK 0001376841 · EVP & Pres-Global Human Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,634 Read SEC document |
| May 02, 2015 Filed May 5, 2015 20:46 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 19,343 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-15-011279 · doc4.xml · nonDerivative · entry 1 Schechter Adam H · CIK 0001376841 · EVP & Pres-Global Human Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,343 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2015 Filed May 5, 2015 20:46 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 235,294 | $0.00 Strike: $59.86 | $0.00 |
DisclosureSEC source: 0001225208-15-011279 · doc4.xml · derivative · entry 4 Schechter Adam H · CIK 0001376841 · EVP & Pres-Global Human Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 235,294 Underlying: Common Stock · 235,294 shares Expires 2025-04-30 F2 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 5/1/2016, 5/1/2017 and 5/1/2018. Read SEC document |
| February 23, 2015 Filed Feb 25, 2015 16:27 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantCommon Stock | 22,198 | $58.30 | $1,294,143.40 |
DisclosureSEC source: 0001225208-15-005609 · doc4.xml · nonDerivative · entry 1 Schechter Adam H · CIK 0001376841 · EVP & Pres-Global Human Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,198 F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 03/30/2012. Performance shares were paid out at 102 percent of target awards. Read SEC document |
| January 15, 2015 Filed Jan 15, 2015 20:55 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (right to buy) · Derivative | 19,200 | $0.00 Strike: $35.09 | $0.00 |
DisclosureSEC source: 0001225208-15-001415 · doc4.xml · derivative · entry 8 Schechter Adam H · CIK 0001376841 · EVP & Pres-Global Human Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 19,200 shares Expires 2016-03-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option became exercisable in equal installments on 3/3/2007, 3/3/2008 and 3/3/2009. Read SEC document |
| January 15, 2015 Filed Jan 15, 2015 20:55 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $44.19 | $0.00 |
DisclosureSEC source: 0001225208-15-001415 · doc4.xml · derivative · entry 7 Schechter Adam H · CIK 0001376841 · EVP & Pres-Global Human Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2017-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option became exercisable in equal installments on 3/2/2008, 3/2/2009 and 3/2/2010. Read SEC document |
| January 15, 2015 Filed Jan 15, 2015 20:55 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $34.47 | $0.00 |
DisclosureSEC source: 0001225208-15-001415 · doc4.xml · derivative · entry 6 Schechter Adam H · CIK 0001376841 · EVP & Pres-Global Human Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2016-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option became exercisable in equal installments on 2/1/2007, 2/1/2008 and 2/1/2009. Read SEC document |
| January 15, 2015 Filed Jan 15, 2015 20:55 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 74,200 | $62.48 | $4,636,223.76 |
DisclosureSEC source: 0001225208-15-001415 · doc4.xml · nonDerivative · entry 4 Schechter Adam H · CIK 0001376841 · EVP & Pres-Global Human Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.1200 to $62.9800, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. Read SEC document |
| January 15, 2015 Filed Jan 15, 2015 20:55 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 5,000 | $34.47 | $172,350.00 |
DisclosureSEC source: 0001225208-15-001415 · doc4.xml · nonDerivative · entry 3 Schechter Adam H · CIK 0001376841 · EVP & Pres-Global Human Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,200 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 15, 2015 Filed Jan 15, 2015 20:55 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 19,200 | $35.09 | $673,728.00 |
DisclosureSEC source: 0001225208-15-001415 · doc4.xml · nonDerivative · entry 2 Schechter Adam H · CIK 0001376841 · EVP & Pres-Global Human Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,200 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 15, 2015 Filed Jan 15, 2015 20:55 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 50,000 | $44.19 | $2,209,500.00 |
DisclosureSEC source: 0001225208-15-001415 · doc4.xml · nonDerivative · entry 1 Schechter Adam H · CIK 0001376841 · EVP & Pres-Global Human Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 24, 2014 Filed Nov 25, 2014 23:57 UTC | Merck & Co., Inc. MRK · Entity 2807 | SalePhantom Stock · Derivative | 2,778.88 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-14-024001 · doc4.xml · derivative · entry 2 Schechter Adam H · CIK 0001376841 · EVP & Pres-Global Human Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,778.88 shares Expires not disclosed F2 · derivative.exercise_price: Each share of phantom stock is the economic equivalent of one share of Merck common stock and was granted under the Merck & Co., Inc. Deferral Program (the "Program"). The Program includes the right of redesignation to other investment measures within the Program. F1 · shares: Holdings include shares acquired in dividend reinvestment transactions. F2 · derivative.exercise_date: Each share of phantom stock is the economic equivalent of one share of Merck common stock and was granted under the Merck & Co., Inc. Deferral Program (the "Program"). The Program includes the right of redesignation to other investment measures within the Program. F2 · derivative.expiration_date: Each share of phantom stock is the economic equivalent of one share of Merck common stock and was granted under the Merck & Co., Inc. Deferral Program (the "Program"). The Program includes the right of redesignation to other investment measures within the Program. Read SEC document |
| August 25, 2014 Filed Aug 25, 2014 19:00 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 22,000 | $59.70 | $1,313,380.20 |
DisclosureSEC source: 0001225208-14-019074 · doc4.xml · nonDerivative · entry 1 Schechter Adam H · CIK 0001376841 · EVP & Pres-Global Human Health 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 70,794.9747 F1 · kind: The sale reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.2600 to $59.85298, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 14, 2014 Filed May 14, 2014 18:48 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 10,527 | $55.91 | $588,583.52 |
DisclosureSEC source: 0001225208-14-012950 · doc4.xml · nonDerivative · entry 1 Schechter Adam H · CIK 0001376841 · EVP & Pres-Global Human Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.7800 to $56.1400, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. Read SEC document |
| May 09, 2014 Filed May 13, 2014 19:55 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 209,078 | $0.00 Strike: $58.22 | $0.00 |
DisclosureSEC source: 0001225208-14-012826 · doc4.xml · derivative · entry 3 Schechter Adam H · CIK 0001376841 · EVP & Pres-Global Human Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 209,078 Underlying: Common Stock · 209,078 shares Expires 2024-05-08 F2 · derivative.exercise_date: The option vests in three equal annual installments beginning May 9, 2015. Read SEC document |
| May 04, 2014 Filed May 6, 2014 20:03 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionRestricted Stock Unit · Derivative | 19,147 | $58.22 | $1,114,738.34 |
DisclosureSEC source: 0001225208-14-012272 · doc4.xml · derivative · entry 4 Schechter Adam H · CIK 0001376841 · EVP & Pres-Global Human Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 19,147 shares Expires 2014-05-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. Read SEC document |
| May 04, 2014 Filed May 6, 2014 20:03 UTC | Merck & Co., Inc. MRK · Entity 2807 | Tax withholdingCommon Stock | 8,620 | $58.22 | $501,856.40 |
DisclosureSEC source: 0001225208-14-012272 · doc4.xml · nonDerivative · entry 2 Schechter Adam H · CIK 0001376841 · EVP & Pres-Global Human Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,527 Read SEC document |
| May 04, 2014 Filed May 6, 2014 20:03 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 19,147 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-14-012272 · doc4.xml · nonDerivative · entry 1 Schechter Adam H · CIK 0001376841 · EVP & Pres-Global Human Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,147 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 24, 2014 Filed Feb 26, 2014 19:24 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantCommon Stock | 22,287 | $56.18 | $1,252,083.66 |
DisclosureSEC source: 0001225208-14-006289 · doc4.xml · nonDerivative · entry 1 Schechter Adam H · CIK 0001376841 · EVP & Pres-Global Human Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,287 F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 03/31/2011. Performance shares were paid out at 86 percent of target awards. Read SEC document |
| February 11, 2014 Filed Feb 13, 2014 15:12 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (right to buy) · Derivative | 3,000 | $0.00 Strike: $45.41 | $0.00 |
DisclosureSEC source: 0001225208-14-004449 · doc4.xml · derivative · entry 9 Schechter Adam H · CIK 0001376841 · EVP & Pres-Global Human Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,000 shares Expires 2014-08-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 11, 2014 Filed Feb 13, 2014 15:12 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (right to buy) · Derivative | 2,500 | $0.00 Strike: $47.39 | $0.00 |
DisclosureSEC source: 0001225208-14-004449 · doc4.xml · derivative · entry 8 Schechter Adam H · CIK 0001376841 · EVP & Pres-Global Human Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,500 shares Expires 2014-05-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 11, 2014 Filed Feb 13, 2014 15:12 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (right to buy) · Derivative | 12,500 | $0.00 Strike: $48.24 | $0.00 |
DisclosureSEC source: 0001225208-14-004449 · doc4.xml · derivative · entry 7 Schechter Adam H · CIK 0001376841 · EVP & Pres-Global Human Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,500 shares Expires 2014-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 11, 2014 Filed Feb 13, 2014 15:12 UTC | Merck & Co., Inc. MRK · Entity 2807 | OtherCommon Stock - 401(k) Plan | 4,040.3746 | $55.70 | $225,048.87 |
DisclosureSEC source: 0001225208-14-004449 · doc4.xml · nonDerivative · entry 5 Schechter Adam H · CIK 0001376841 · EVP & Pres-Global Human Health 10b5-1 filing: Not disclosed Ownership: Indirect · By 401(k) Disclosed balance after: 0 F2 · shares: Includes 97.2259 shares acquired under the Merck U.S. Savings Plan, a 401(k) plan, since the date of the reporting person's last ownership report. Read SEC document |
| February 11, 2014 Filed Feb 13, 2014 15:12 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 18,000 | $55.61 | $1,000,935.00 |
DisclosureSEC source: 0001225208-14-004449 · doc4.xml · nonDerivative · entry 4 Schechter Adam H · CIK 0001376841 · EVP & Pres-Global Human Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.52 to $55.72, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. Read SEC document |
| February 11, 2014 Filed Feb 13, 2014 15:12 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 2,500 | $47.39 | $118,475.00 |
DisclosureSEC source: 0001225208-14-004449 · doc4.xml · nonDerivative · entry 3 Schechter Adam H · CIK 0001376841 · EVP & Pres-Global Human Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 11, 2014 Filed Feb 13, 2014 15:12 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 3,000 | $45.41 | $136,230.00 |
DisclosureSEC source: 0001225208-14-004449 · doc4.xml · nonDerivative · entry 2 Schechter Adam H · CIK 0001376841 · EVP & Pres-Global Human Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 11, 2014 Filed Feb 13, 2014 15:12 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 12,500 | $48.24 | $603,000.00 |
DisclosureSEC source: 0001225208-14-004449 · doc4.xml · nonDerivative · entry 1 Schechter Adam H · CIK 0001376841 · EVP & Pres-Global Human Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 07, 2013 Filed May 8, 2013 23:28 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionRestricted Stock Unit · Derivative | 12,188 | $44.98 | $548,216.24 |
DisclosureSEC source: 0001225208-13-011734 · doc4.xml · derivative · entry 6 Schechter Adam H · CIK 0001376841 · EVP & Pres-Global Human Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,188 shares Expires 2013-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. Read SEC document |
| May 07, 2013 Filed May 8, 2013 23:28 UTC | Merck & Co., Inc. MRK · Entity 2807 | Tax withholdingCommon Stock | 5,488 | $44.98 | $246,850.24 |
DisclosureSEC source: 0001225208-13-011734 · doc4.xml · nonDerivative · entry 2 Schechter Adam H · CIK 0001376841 · EVP & Pres-Global Human Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,415.57 F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 07, 2013 Filed May 8, 2013 23:28 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 12,188 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-13-011734 · doc4.xml · nonDerivative · entry 1 Schechter Adam H · CIK 0001376841 · EVP & Pres-Global Human Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,903.57 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 06, 2013 Filed May 8, 2013 23:28 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 244,767 | $0.00 Strike: $44.98 | $0.00 |
DisclosureSEC source: 0001225208-13-011734 · doc4.xml · derivative · entry 5 Schechter Adam H · CIK 0001376841 · EVP & Pres-Global Human Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 244,767 Underlying: Common Stock · 244,767 shares Expires 2023-05-05 F3 · derivative.exercise_date: The option vests in three equal annual installments beginning May 6, 2014. Read SEC document |
| February 25, 2013 Filed Feb 27, 2013 22:50 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantCommon Stock | 8,136 | $42.52 | $345,942.72 |
DisclosureSEC source: 0001225208-13-005769 · doc4.xml · nonDerivative · entry 1 Schechter Adam H · CIK 0001376841 · EVP & Pres-Global Human Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,568 F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/31/2010. Performance shares were paid out at 107 percent of target awards. Read SEC document |
| February 19, 2013 Filed Feb 20, 2013 22:34 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionRestricted Stock Unit · Derivative | 10,670 | $41.42 | $441,951.40 |
DisclosureSEC source: 0001225208-13-004733 · doc4.xml · derivative · entry 5 Schechter Adam H · CIK 0001376841 · EVP & Pres-Global Human Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,670 shares Expires 2013-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. Read SEC document |
| February 19, 2013 Filed Feb 20, 2013 22:34 UTC | Merck & Co., Inc. MRK · Entity 2807 | Tax withholdingCommon Stock | 3,238 | $41.42 | $134,117.96 |
DisclosureSEC source: 0001225208-13-004733 · doc4.xml · nonDerivative · entry 2 Schechter Adam H · CIK 0001376841 · EVP & Pres-Global Human Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,432 F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| February 19, 2013 Filed Feb 20, 2013 22:34 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 10,670 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-13-004733 · doc4.xml · nonDerivative · entry 1 Schechter Adam H · CIK 0001376841 · EVP & Pres-Global Human Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,670 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 05, 2012 Filed Nov 6, 2012 22:03 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $28.42 | $0.00 |
DisclosureSEC source: 0001225208-12-022534 · doc4.xml · derivative · entry 9 Schechter Adam H · CIK 0001376841 · EVP & Pres-Global Human Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2015-10-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 05, 2012 Filed Nov 6, 2012 22:03 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (right to buy) · Derivative | 61,200 | $0.00 Strike: $23.45 | $0.00 |
DisclosureSEC source: 0001225208-12-022534 · doc4.xml · derivative · entry 8 Schechter Adam H · CIK 0001376841 · EVP & Pres-Global Human Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 61,200 shares Expires 2019-04-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 05, 2012 Filed Nov 6, 2012 22:03 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $31.84 | $0.00 |
DisclosureSEC source: 0001225208-12-022534 · doc4.xml · derivative · entry 7 Schechter Adam H · CIK 0001376841 · EVP & Pres-Global Human Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2015-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 05, 2012 Filed Nov 6, 2012 22:03 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 56,300 | $45.60 | $2,567,257.48 |
DisclosureSEC source: 0001225208-12-022534 · doc4.xml · nonDerivative · entry 4 Schechter Adam H · CIK 0001376841 · EVP & Pres-Global Human Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,900 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.5900 to $45.6050, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. Read SEC document |
| November 05, 2012 Filed Nov 6, 2012 22:03 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 5,000 | $28.42 | $142,100.00 |
DisclosureSEC source: 0001225208-12-022534 · doc4.xml · nonDerivative · entry 3 Schechter Adam H · CIK 0001376841 · EVP & Pres-Global Human Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,200 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 05, 2012 Filed Nov 6, 2012 22:03 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 5,000 | $31.84 | $159,200.00 |
DisclosureSEC source: 0001225208-12-022534 · doc4.xml · nonDerivative · entry 2 Schechter Adam H · CIK 0001376841 · EVP & Pres-Global Human Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,200 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 05, 2012 Filed Nov 6, 2012 22:03 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 61,200 | $23.45 | $1,435,140.00 |
DisclosureSEC source: 0001225208-12-022534 · doc4.xml · nonDerivative · entry 1 Schechter Adam H · CIK 0001376841 · EVP & Pres-Global Human Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,200 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 02, 2012 Filed May 4, 2012 13:40 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 277,879 | $0.00 Strike: $39.29 | $0.00 |
DisclosureSEC source: 0001225208-12-011191 · doc4.xml · derivative · entry 5 Schechter Adam H · CIK 0001376841 · EVP & Pres-Global Human Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 277,879 Underlying: Common Stock · 277,879 shares Expires 2022-05-01 F4 · derivative.exercise_date: The option vests in three equal annual installments beginning May 2, 2013. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.